Neuroendocrine Tumors: Diagnostic Workup and Treatment Approach
For suspected neuroendocrine tumors, begin with baseline chromogranin A (CgA) and 24-hour urinary 5-HIAA, followed by multimodality imaging including CT/MRI and somatostatin receptor scintigraphy (SSRS), with surgery as first-line treatment for localized disease and somatostatin analogs for metastatic or functional tumors 1, 2, 3.
Initial Diagnostic Workup
Clinical Assessment
- Obtain detailed family history to exclude MEN1 syndrome or other familial syndromes—critical in all NET cases 1
- Screen for second endocrine tumors and other gut cancers in all patients 1
- Identify functional syndromes: carcinoid syndrome (flushing, diarrhea), Zollinger-Ellison (gastrinoma), hypoglycemia (insulinoma), or other hormone excess states 2
Biochemical Testing
Baseline tests for all suspected cases 1, 2:
- Chromogranin A (CgA) - general NET marker (note: proton pump inhibitors cause false elevations)
- 24-hour urinary 5-HIAA - essential for midgut NETs/carcinoid syndrome
- Additional markers based on clinical syndrome:
- Gastrin (if Zollinger-Ellison suspected)
- Insulin/C-peptide (if hypoglycemia)
- Glucagon, VIP, pancreatic polypeptide (if specific pancreatic NET syndromes)
- NSE (if CgA normal, particularly in poorly differentiated tumors)
Imaging Strategy
Use a multimodality approach 1, 4, 2:
Somatostatin receptor imaging (first-line functional imaging) 4, 2:
- CT or MRI (site-dependent) for precise anatomical localization
- MRI preferred for pancreatic and liver lesions
- Gastroscopy, colonoscopy, or capsule endoscopy based on suspected primary site
- Endoscopic ultrasound (EUS) for pancreatic and duodenal lesions—allows tissue sampling
FDG-PET 4:
- Reserve for poorly differentiated/high-grade (G3) tumors
- Not useful for well-differentiated NETs
Histopathology Requirements
Tissue diagnosis is mandatory 2, 3:
- Confirm neuroendocrine markers: chromogranin A, synaptophysin
- Ki-67 proliferation index is critical for grading 4, 2:
- Grade 1 (G1): Ki-67 ≤2%
- Grade 2 (G2): Ki-67 3-20%
- Grade 3 (G3): Ki-67 >20%
- Grading directly impacts treatment selection and prognosis
Treatment Algorithm
Localized Disease (No Metastases)
Surgery is the primary curative treatment 1, 2, 3:
- Offer resection to all fit patients with limited disease (primary + regional nodes) 1
- Consider cholecystectomy during abdominal surgery if long-term somatostatin analog therapy anticipated 1
- Aim for R0 resection when feasible
Metastatic Disease - Treatment Selection by Tumor Type
Well-Differentiated Midgut/Small Intestinal NETs (G1/G2)
First-line: Somatostatin analogs 2, 3:
- Octreotide LAR or lanreotide for both symptom control and antiproliferative effect
- Second-line: PRRT with 177Lu-DOTATATE for progressive disease on SSAs 3—this is now EMA and FDA approved with strong evidence (ESMO-MCBS score: 4)
- Everolimus can be considered after PRRT failure 3
- Avoid chemotherapy in slowly growing well-differentiated GI NETs 3—response rates are poor (<10%)
Pancreatic NETs (Pan-NETs)
Treatment sequence depends on grade and progression 2, 3, 5:
For progressive Pan-NETs G1/G2:
- Everolimus (10 mg daily) or sunitinib (37.5 mg daily)—both EMA-approved with Level I evidence 3, 5
- Chemotherapy options 2, 3:
- STZ/5-FU (streptozocin/5-fluorouracil) for progressive disease
- Temozolomide ± capecitabine—promising alternative with 70% response rates in some series 2
- PRRT with 177Lu-DOTATATE after failure of approved therapies 3
Common pitfall: Somatostatin analogs should be used cautiously in insulinomas as they may transiently worsen hypoglycemia 5.
Poorly Differentiated Neuroendocrine Carcinoma (NEC G3)
Platinum-based chemotherapy is standard 2, 3:
- Cisplatin or carboplatin + etoposide as first-line 2, 3
- Response rates: 42-67% but short duration (8-9 months) 2
- Second-line options: FOLFIRI, FOLFOX, or temozolomide-based regimens 3
- Do not use everolimus or sunitinib in NEC G3 outside clinical trials 3
Well-Differentiated NET G3
Important distinction from NEC G3 3:
- NET G3 responds poorly to cisplatin/etoposide—do not use this combination 3
- Consider PRRT in carefully selected patients 3
- May respond to temozolomide-based regimens
Asymptomatic/Stable Disease
Observation is appropriate 5:
- Monitor with biochemical markers and imaging every 3-12 months
- Consider somatostatin analogs even without progression for antiproliferative effect
Liver-Directed Therapies
Consider for unresectable liver metastases 1, 5:
- Hepatic arterial embolization, chemoembolization, or radioembolization
- Radiofrequency ablation for limited lesions
- Cytoreductive surgery in select cases with potentially resectable disease 1
Follow-Up Strategy
Tailor surveillance to grade and resection status 2, 3:
- R0/R1 resected NET G1/G2: Imaging (CT/MRI) every 3-6 months
- NEC G3: Imaging every 2-3 months due to aggressive biology
- Somatostatin receptor imaging: Repeat at 18-24 months if SSTR2a expression confirmed 2
- Biochemical markers: Serial CgA (or NSE if CgA not elevated) 2
- Consider re-biopsy of liver metastases if rapid progression to reassess Ki-67 2
Critical Nuances
The 2005 Gut guidelines [1-1 provide the foundational framework but are now outdated. More recent ESMO 2020 guidelines 3 and NCCN 2015/2021 5, 6 incorporate critical advances:
- PRRT with 177Lu-DOTATATE is now standard second-line for midgut NETs (not available when 2005 guidelines published)
- 68Ga-DOTATATE PET/CT has replaced older Octreoscan
- Recognition of NET G3 as distinct from NEC G3 with different treatment implications
- Everolimus and sunitinib now have Level I evidence in Pan-NETs
Quality of life is paramount in non-resectable disease 1—treatment aims to maintain optimal QOL, not just tumor response. This is particularly relevant given the often indolent nature of well-differentiated NETs where aggressive chemotherapy may cause more harm than benefit.